Nasopharyngeal
Carcinoma
Dr. Krishna
Koirala
2016-05-202016-05-20
Introduction
• Nasopharyngeal carcinoma is a non -
lymphomatous squamous-cell carcinoma
that occurs in the epithelial lining of the
nasopharynx
• It frequently arises from the pharyngeal
recess (fossa of Rosenmüller)
Epidemiology
•Accounts for 85% adult nasopharyngeal
malignancies and 30% pediatric nasopharyngeal
malignancies
•Race : Common in Chinese & North African
people
•Sex : Male preponderance of 3:1
•Age : Bimodal presentation with Small peak
at 15-25 yrs and a large peak at 55-65yrs
•Gross : Proliferative, Ulcerative & Infiltrative
types
Etiology
• Genetic
• Commonest in Southern Chinese population
( Mongoloid race)
• HLA – A ,B and DR loci situated on the short
arm of chromosome 6
• Viral : Epstein-Barr Virus
• Environmental
• Exposure to nitrosamines (dry salted fish),
polycyclic hydrocarbons (smoke from incense
& wood)
• Smoking , chronic nasal infection, poor
W.H.O. Classification
(Histological)
Type 1:
• Keratinizing squamous cell carcinoma
Type 2:
• Non-keratinizing (transitional)
carcinoma
Type 3:
• Undifferentiated (anaplastic) carcinoma
Clinical Features
1. Neck swelling (60%)
• Lateral retropharyngeal LN of Rouviere
• B/L, enlarged jugulodigastric, upper &
middle deep cervical nodes and
posterior triangle nodes
2. Nasal (40%)
• Blood stained nasal mucus, epistaxis,
nose block, foul smelling nasal
4. Ophthalmologic (20%)
• Diplopia & ophthalmoplegia
(involvement of CN III, IV, VI), Proptosis
(orbit invasion) & blindness
(involvement of CN II)
5. Neurologic (20 %)
• Jugular foramen syndrome: CN IX, X, XI
involved by lateral retropharyngeal
lymph node
6. Severe Headache
• Skull base erosion
7. Trotter's triad
• Conductive deafness: Eustachian Tube
block
• Ipsilateral temporo -parietal neuralgia:
Trigeminal nerve involvement
• Ipsilateral palatal paralysis: Vagus
nerve damage
Investigations
1. Nasopharyngoscopy & Diagnostic Nasal
Endoscopy
• Mass seen in nasopharynx at fossa of
Rosenmüller
2. Nasopharyngeal tumor biopsy: blind
/under vision
3. F.N.A.C. of neck node: done in occult
primary
5. M.R.I. head & neck: for intracranial
extension.
6. Tests for metastases
• C.T. chest and abdomen, bone scan,
P.E.T. scan, liver function tests
7. Serologic tests
• Immuno-fluorescence for IgA antibodies
to Viral Capsid Antigen, Ig G antibodies
to Early Antigen
Diagnostic Nasal Endoscopy
Computerized Tomogram Scan
CT scan: retropharyngeal
node
CT scan: Infratemporal fossa
& orbit involvement
CT scan: Sella involvement
Magnetic Resonance Imaging
M.R.I.: intracranial extension
Endoscopic Biopsy
Whole body bone scan
Positron Emission Tomography
T.N.M. staging
T1 = confined to nasopharynx
T2 = soft tissue involvement in oropharynx
or nasal cavity or Parapharyngeal space
T3 = invasion of bony structures or P.N.S.
T4 = intracranial, involvement of orbit,
cranial
N0 = no evidence of regional lymph nodes
N1 = unilateral N2 = bilateral
(Both are above supraclavicular fossa & <
6 cm)
N3 = > 6 cm or in supraclavicular fossa
M0 = no evidence of distant metastasis
T.N.M. staging
• Stage I = T1 N0 M0
• Stage II = T2 or N1 M0
• Stage III = T3 or N2 M0
• Stage IV = T4 or N3 or M1
Treatment modalities
1. Teletherapy or External beam
radiotherapy
2. Brachytherapy
3. Chemotherapy
4. Surgery
5. Immunotherapy against E.B.V.
External beam irradiation
• 2 lateral fields: nasopharynx, skull base &
upper neck sparing temporal lobe, pituitary
& spinal cord
• 1 anterior field: lower neck; sparing spinal
cord & larynx
Brachytherapy
• Used for small tumor, residual or
recurrent tumor
• Interstitial: Radioactive source (Radium,
Iridium, Iodine, Gold) inserted into tumor
tissue
• Intracavitary: Radioactive source placed
inside the catheter or moulds & inserted
into nasopharynx
Interstitial Brachytherapy
Intracavitary Brachytherapy
High Dose Rate Brachytherapy
Chemotherapy
Drugs used
1. Cisplatin
2. 5-Fluorouracil
Indications
1. Radiation failure
2. Palliation in distant metastasis
Surgery
1. Nasopharyngectomy, Cryosurgery : for
residual or recurrent tumor
2. Radical neck dissection: for radio-
resistant neck node metastasis
3. Palliative debulking: for T4 tumors
4. Myringotomy & grommet insertion: for
persistent otitis media with effusion
Radical neck dissection &
Interstitial Brachytherapy
Treatment Protocol
T1 = External Radiotherapy (6500 c Gy)
T2 = External Radiotherapy (7000 c Gy)
T3 & T4 = Radiotherapy + Chemotherapy →
Brachytherapy / Salvage surgery if
required
N0 = External Radiotherapy (5000 c Gy)
Prognosis
• W.H.O. Type 2 & 3 carcinomas have good
response to radiotherapy & better
survival rates
• Average 5 year survival rates for treated
patients
Stage I = 95 – 100 %
Stage II = 60 – 80 %
Stage III = 30 – 60 %

Nasopharyngeal carcinoma

  • 1.
  • 2.
    Introduction • Nasopharyngeal carcinomais a non - lymphomatous squamous-cell carcinoma that occurs in the epithelial lining of the nasopharynx • It frequently arises from the pharyngeal recess (fossa of Rosenmüller)
  • 3.
    Epidemiology •Accounts for 85%adult nasopharyngeal malignancies and 30% pediatric nasopharyngeal malignancies •Race : Common in Chinese & North African people •Sex : Male preponderance of 3:1 •Age : Bimodal presentation with Small peak at 15-25 yrs and a large peak at 55-65yrs •Gross : Proliferative, Ulcerative & Infiltrative types
  • 4.
    Etiology • Genetic • Commonestin Southern Chinese population ( Mongoloid race) • HLA – A ,B and DR loci situated on the short arm of chromosome 6 • Viral : Epstein-Barr Virus • Environmental • Exposure to nitrosamines (dry salted fish), polycyclic hydrocarbons (smoke from incense & wood) • Smoking , chronic nasal infection, poor
  • 5.
    W.H.O. Classification (Histological) Type 1: •Keratinizing squamous cell carcinoma Type 2: • Non-keratinizing (transitional) carcinoma Type 3: • Undifferentiated (anaplastic) carcinoma
  • 6.
    Clinical Features 1. Neckswelling (60%) • Lateral retropharyngeal LN of Rouviere • B/L, enlarged jugulodigastric, upper & middle deep cervical nodes and posterior triangle nodes 2. Nasal (40%) • Blood stained nasal mucus, epistaxis, nose block, foul smelling nasal
  • 7.
    4. Ophthalmologic (20%) •Diplopia & ophthalmoplegia (involvement of CN III, IV, VI), Proptosis (orbit invasion) & blindness (involvement of CN II) 5. Neurologic (20 %) • Jugular foramen syndrome: CN IX, X, XI involved by lateral retropharyngeal lymph node
  • 8.
    6. Severe Headache •Skull base erosion 7. Trotter's triad • Conductive deafness: Eustachian Tube block • Ipsilateral temporo -parietal neuralgia: Trigeminal nerve involvement • Ipsilateral palatal paralysis: Vagus nerve damage
  • 10.
    Investigations 1. Nasopharyngoscopy &Diagnostic Nasal Endoscopy • Mass seen in nasopharynx at fossa of Rosenmüller 2. Nasopharyngeal tumor biopsy: blind /under vision 3. F.N.A.C. of neck node: done in occult primary
  • 11.
    5. M.R.I. head& neck: for intracranial extension. 6. Tests for metastases • C.T. chest and abdomen, bone scan, P.E.T. scan, liver function tests 7. Serologic tests • Immuno-fluorescence for IgA antibodies to Viral Capsid Antigen, Ig G antibodies to Early Antigen
  • 12.
  • 13.
  • 14.
  • 15.
    CT scan: Infratemporalfossa & orbit involvement
  • 16.
    CT scan: Sellainvolvement
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
    T.N.M. staging T1 =confined to nasopharynx T2 = soft tissue involvement in oropharynx or nasal cavity or Parapharyngeal space T3 = invasion of bony structures or P.N.S. T4 = intracranial, involvement of orbit, cranial
  • 23.
    N0 = noevidence of regional lymph nodes N1 = unilateral N2 = bilateral (Both are above supraclavicular fossa & < 6 cm) N3 = > 6 cm or in supraclavicular fossa M0 = no evidence of distant metastasis
  • 24.
    T.N.M. staging • StageI = T1 N0 M0 • Stage II = T2 or N1 M0 • Stage III = T3 or N2 M0 • Stage IV = T4 or N3 or M1
  • 25.
    Treatment modalities 1. Teletherapyor External beam radiotherapy 2. Brachytherapy 3. Chemotherapy 4. Surgery 5. Immunotherapy against E.B.V.
  • 26.
    External beam irradiation •2 lateral fields: nasopharynx, skull base & upper neck sparing temporal lobe, pituitary & spinal cord • 1 anterior field: lower neck; sparing spinal cord & larynx
  • 27.
    Brachytherapy • Used forsmall tumor, residual or recurrent tumor • Interstitial: Radioactive source (Radium, Iridium, Iodine, Gold) inserted into tumor tissue • Intracavitary: Radioactive source placed inside the catheter or moulds & inserted into nasopharynx
  • 28.
  • 29.
  • 30.
    High Dose RateBrachytherapy
  • 31.
    Chemotherapy Drugs used 1. Cisplatin 2.5-Fluorouracil Indications 1. Radiation failure 2. Palliation in distant metastasis
  • 32.
    Surgery 1. Nasopharyngectomy, Cryosurgery: for residual or recurrent tumor 2. Radical neck dissection: for radio- resistant neck node metastasis 3. Palliative debulking: for T4 tumors 4. Myringotomy & grommet insertion: for persistent otitis media with effusion
  • 33.
    Radical neck dissection& Interstitial Brachytherapy
  • 34.
    Treatment Protocol T1 =External Radiotherapy (6500 c Gy) T2 = External Radiotherapy (7000 c Gy) T3 & T4 = Radiotherapy + Chemotherapy → Brachytherapy / Salvage surgery if required N0 = External Radiotherapy (5000 c Gy)
  • 35.
    Prognosis • W.H.O. Type2 & 3 carcinomas have good response to radiotherapy & better survival rates • Average 5 year survival rates for treated patients Stage I = 95 – 100 % Stage II = 60 – 80 % Stage III = 30 – 60 %